Pan-TPF

None

Fluorinated pyrimidine; antimetabolite. FDA approved uses on basal cell carcinoma, breast cancer, colorectal cancer, gastric cancer, and pancreatic cancer.

Note: Efudex cream be prescribed to treat AIN III. Code this as chemotherapy.

This drug should be coded

None

None

FDA approved for use on breast, prostate, stomach and NSCLC. Aventis Pharmaceuticals.

This drug should be coded

None

None

FDA approved for colorectal 2006. The FDA categorized this agent as chemotherapy.
May 2014 Update: The FDA approved vectibix for use in combination with FOLFOX as a first-line treatment in patients with wild-type KRAS metastatic colorectal cancer

November 18, 2015: IMPORTANT UPDATE- CATEGORY CHANGE-After careful review, panitumumab has changed categories from chemotherapy to BRM/Immunotherapy. This drug was originally classified as a chemotherapeutic agent by the FDA in 2006. The Physicians Cancer Chemotherapy Drug Manual states this drug is an immunotherapy agent as far back as 2007. You do not need to review and recode old cases but may immediately begin coding this agent as immunotherapy. It is important to note SEER*RX follows FDA guidelines for assigning drug categories and any update to this drug may not have been received by SEER.

6/30/2017
FDA approved the supplemental Biologics License Application for Vectibix (panitumumab) for patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer as first-line therapy in combination with FOLFOX and as monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy.
Vectibix is the first-and-only fully human monoclonal anti-epidermal growth factor receptor antibody approved by the FDA for this patient population.

This drug should be coded

None

An alkylating antineoplastic agent. FDA approved uses on bladder, ovarian and testicular cancer; miscellaneous agent.

This drug should be coded